查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
生化防御的全球市场 - 全球产业分析(2019年～2022年)- 成长趋势与市场预测(2023年～2030年)
市场调查报告书
商品编码
1272004

生化防御的全球市场 - 全球产业分析(2019年～2022年)- 成长趋势与市场预测(2023年～2030年)

Biodefense Market - Global Industry Analysis (2019 - 2022), Growth Trends, and Market Forecast (2023 - 2030)
出版日期: | 出版商: Fairfield Market Research | 英文 175 Pages | 商品交期: 2-5个工作天内

价格
简介目录

全球生化防御的市场规模在2022年估算为148亿美金。该市场在预测期间内预计将以6.3％的年复合成长率扩大，2030年达到245亿美元。

本报告提供全球生化防御市场相关调查，提供市场概要，以及各产品类型，各最终用途类型，各地区趋势，及市场参与市场企业的竞争趋势等资讯。

目录

第1章 摘要整理

第2章 市场概要

第3章 全球生化防御市场预测，2019年～2030年

  • 全球生化防御市场预测，各产品类型，2019年～2030年
  • 全球生化防御市场预测，各最终用途类型，2019年～2030年
  • 全球生化防御市场预测，各地区，2019年～2030年

第4章 北美的生化防御市场预测，2019年～2030年

第5章 欧洲的生化防御市场预测，2019年～2030年

第6章 亚太地区的生化防御市场预测，2019年～2030年

第7章 其他地区的生化防御市场预测，2019年～2030年

第8章 竞争情形

  • 热图分析
  • 企业简介
    • Emergent Biosolutions, Inc.
    • SIGA Technologies, Inc.
    • Bavarian Nordik A/S
    • GSK plc
    • Sanofi Pasteur
    • NightHawk Biosciences, Inc.
    • Soligenix
    • Arbutus Biopharma Corporation
    • Altimmune
    • Meridian Medical Technologies, LLC
    • 其他

第9章 附录

简介目录

The confluence of rising concerns about biothreats and the emergence of infectious diseases has created a demand for biodefense products and services. Recognising this need, government authorities worldwide are making significant investments in biodefense research, development, and procurement programs to ensure public health preparedness and enhance national security. Such a scenario is also influencing strategic partnerships among key players in the biodefense market. These collaborations aim to enhance their capabilities, expand their product portfolios, and strengthen their market presence. Furthermore, the advances in biotechnology, genomics, and proteomics are facilitating the development of innovative biodefense products, and services with enhanced efficacy, specificity, and rapidity.

Additionally, the increasing public awareness of the potential impact of biothreats on health and national security is accelerating efforts to develop biodefense measures. In its latest report, Fairfield Market Research foresees the growth trajectory for the global biodefense market. Registering a revenue worth US$14.8 Bn in 2022, the market is slated for a substantial CAGR of 6.3% over the forecast period and is expected to reach a whopping US$24.5 Bn by 2030.

Key Insights and Trends Across Biodefense Market:

  • Anthrax category to emerge as a leading product type, accounting for a lion share (30%) of the market
  • Military segment to establish itself as a frontrunner in the global biodefense market, exhibiting a robust CAGR of 6.2%
  • North America to sustain market dominance owing to favourable federal funding, reaching a staggering US$20.8 billion by the end of 2030

Infectious Diseases Pose Mounting Threat to Global Health, Spurring Explosive Growth Across Biodefense Market:

Over recent years, the risk of infectious diseases, due to the accidental or deliberate release of chemical, biological, radiological, or nuclear (CBRN) agents, has increased. This in turn has prompted biodefense firms to develop sophisticated diagnostic tools that can detect a wide array of infectious agents, including viruses, bacteria, and fungi. Companies are also investing in research and development to create innovative therapeutics and vaccines. Currently, there is a range of prophylactic, therapeutic, and diagnostic products available for significant biological, chemical and radiation threats. In light of these circumstances, the global biodefense market is projected to gain substantial momentum in the upcoming years.

Advanced Healthcare Infrastructure Puts North America at the Forefront of Global Biodefense Market:

North America is well-positioned to attain a distinct advantage in the global biodefense market. This is primarily attributable to the strong and effective strategies of the United States government. Besides, North America has made significant investments in research and development activities and procurement programs. Apart from this, the region also boasts a well-developed healthcare infrastructure with modern diagnostic and treatment facilities that enable rapid detection and response to biodefense. Such trends are sowing the seed of sustainable growth across North America's biodefense market.

Prominent Market Players:

Some of the key players in the global biodefense market include: Nanotherapeutics, Inc., SIGA Technologies, Inc., Emergent BioSolutions, Inc., Altimmune, Inc., Bavarian Nordic A/S, Statera Biopharma, Inc., GSK plc. Sanofi Pasteur, Dynavax Technologies Corporation, Xoma Corporation, Meridian Medical Technologies, NightHawk Biosciences, Inc., Dynport Vaccine Company LLC, LLC, and Soligenix.

Table of Contents

1. Executive Summary

  • 1.1. Global Biodefense Market Outlook, 2019 - 2030 (US$ Million)
  • 1.2. Global Biodefense Market Incremental Opportunity, 2023 - 2030 (US$ Million)
  • 1.3. Key Industry Trends

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Market Drivers
    • 2.2.2. Market Threats
    • 2.2.3. Market Opportunities
  • 2.3. Regulatory Framework
  • 2.4. COVID 19 Impact Analysis

3. Global Biodefense Market Outlook, 2019 - 2030

  • 3.1. Global Biodefense Market Outlook, By Product Type, 2019 - 2030
    • 3.1.1. Key Highlights
    • 3.1.2. Global Biodefense Market Outlook, by Product Type, Value (US$ Million), 2019 - 2030
      • 3.1.2.1. Anthrax
      • 3.1.2.2. Smallpox
      • 3.1.2.3. Botulism
      • 3.1.2.4. Chemical
      • 3.1.2.5. Radiation/Nuclear
      • 3.1.2.6. Others
    • 3.1.3. Global Biodefense Market Share and BPS Analysis, by Product Type, Value, 2023 and 2030
    • 3.1.4. Global Biodefense Market Attractiveness Analysis, by Product Type, Value, 2023 - 2030
  • 3.2. Global Biodefense Market Outlook, By End Use Type, 2019 - 2030
    • 3.2.1. Key Highlights
    • 3.2.2. Global Biodefense Market Outlook, by End Use Type, Value (US$ Million), 2019 - 2030
      • 3.2.2.1. Military
      • 3.2.2.2. Civil
      • 3.2.2.3. Research Institutes
    • 3.2.3. Global Biodefense Market Share and BPS Analysis, by End Use Type, Value, 2023 and 2030
    • 3.2.4. Global Biodefense Market Attractiveness Analysis, by End Use Type, Value, 2023 - 2030
  • 3.3. Global Biodefense Market Outlook, By Region, 2019 - 2030
    • 3.3.1. Key Highlights
    • 3.3.2. Global Biodefense Market Outlook, by Region, Value (US$ Million), 2019 - 2030
      • 3.3.2.1. North America
      • 3.3.2.2. Europe
      • 3.3.2.3. Asia Pacific
      • 3.3.2.4. Rest of the World
    • 3.3.3. Global Biodefense Market Share and BPS Analysis, by Region, Value, 2023 and 2030
    • 3.3.4. Global Biodefense Market Attractiveness Analysis, by Region, Value, 2023 - 2030

4. North America Biodefense Market Outlook, 2019 - 2030

  • 4.1. North America Biodefense Market Outlook, By Country, 2019 - 2030
    • 4.1.1. Key Highlights
    • 4.1.2. North America Biodefense Market Outlook, by Country, Value (US$ Million), 2019 - 2030
      • 4.1.2.1. U.S.
      • 4.1.2.2. Canada
    • 4.1.3. North America Biodefense Market Share and BPS Analysis, by Country, Value, 2023 and 2030
    • 4.1.4. North America Biodefense Market Attractiveness Analysis, by Country, Value, 2023 - 2030
  • 4.2. North America Biodefense Market Outlook, by Product Type, 2019 - 2030
    • 4.2.1. Key Highlights
    • 4.2.2. North America Biodefense Market Outlook, by Product Type, Value (US$ Million), 2019 - 2030
      • 4.2.2.1. Anthrax
      • 4.2.2.2. Smallpox
      • 4.2.2.3. Botulism
      • 4.2.2.4. Chemical
      • 4.2.2.5. Radiation/Nuclear
      • 4.2.2.6. Others
    • 4.2.3. North America Biodefense Market Share and BPS Analysis, by Product Type, Value, 2023 and 2030
    • 4.2.4. North America Biodefense Market Attractiveness Analysis, by Product Type, Value, 2023 - 2030
  • 4.3. North America Biodefense Market Outlook, by End Use, 2019 - 2030
    • 4.3.1. Key Highlights
    • 4.3.2. North America Biodefense Market Outlook, by End Use, Value (US$ Million), 2019 - 2030
      • 4.3.2.1. Military
      • 4.3.2.2. Civil
      • 4.3.2.3. Research Institutes
    • 4.3.3. North America Biodefense Market Share and BPS Analysis, by End Use, Value, 2023 and 2030
    • 4.3.4. North America Biodefense Market Attractiveness Analysis, by End Use, Value, 2023 - 2030

5. Europe Biodefense Market Outlook, 2019 - 2030

  • 5.1. Europe Biodefense Market Outlook, By Country, 2019 - 2030
    • 5.1.1. Key Highlights
    • 5.1.2. Europe Biodefense Market Outlook, by Country, Value (US$ Million), 2019 - 2030
      • 5.1.2.1. U.K.
      • 5.1.2.2. France
      • 5.1.2.3. Germany
      • 5.1.2.4. Italy
      • 5.1.2.5. Spain
      • 5.1.2.6. Rest of Europe
    • 5.1.3. Europe Biodefense Market Share and BPS Analysis, by Country, Value, 2023 and 2030
    • 5.1.4. Europe Biodefense Market Attractiveness Analysis, by Country, Value, 2023 - 2030
  • 5.2. Europe Biodefense Market Outlook, by Product Type, Value (US$ Million), 2019 - 2030
    • 5.2.1. Key Highlights
    • 5.2.2. Europe Biodefense Market Outlook, by Product Type, Value (US$ Million), 2019 - 2030
      • 5.2.2.1. Anthrax
      • 5.2.2.2. Smallpox
      • 5.2.2.3. Botulism
      • 5.2.2.4. Chemical
      • 5.2.2.5. Radiation/Nuclear
      • 5.2.2.6. Others
    • 5.2.3. Europe Biodefense Market Share and BPS Analysis, by Product Type, Value, 2023 and 2030
    • 5.2.4. Europe Biodefense Market Attractiveness Analysis, by Product Type, Value, 2023 - 2030
  • 5.3. Europe Biodefense Market Outlook, By End Use Type, 2019 - 2030
    • 5.3.1. Key Highlights
    • 5.3.2. Europe Biodefense Market Outlook, by End Use Type, Value (US$ Million), 2019 - 2030
      • 5.3.2.1. Military
      • 5.3.2.2. Civil
      • 5.3.2.3. Research Institutes
    • 5.3.3. Europe Biodefense Market Share and BPS Analysis, by End Use, Value, 2023 and 2030
    • 5.3.4. Europe Biodefense Market Attractiveness Analysis, by End Use, Value, 2023 - 2030

6. Asia Pacific Biodefense Market Outlook, 2019 - 2030

  • 6.1. Asia Pacific Biodefense Market Outlook, By Country, 2019 - 2030
    • 6.1.1. Key Highlights
    • 6.1.2. Asia Pacific Biodefense Market Outlook, by Country, Value (US$ Million), 2019 - 2030
      • 6.1.2.1. India
      • 6.1.2.2. Japan
      • 6.1.2.3. China
      • 6.1.2.4. Australia
      • 6.1.2.5. Rest of Asia Pacific
    • 6.1.3. Asia Pacific Biodefense Market Share and BPS Analysis, by Country, Value, 2023 and 2030
    • 6.1.4. Asia Pacific Biodefense Market Attractiveness Analysis, by Country, Value, 2023 - 2030
  • 6.2. Asia Pacific Biodefense Market Outlook, by Product Type, Value (US$ Million), 2019 - 2030
    • 6.2.1. Key Highlights
    • 6.2.2. Asia Pacific Biodefense Market Outlook, by Product Type, Value (US$ Million), 2019 - 2030
      • 6.2.2.1. Anthrax
      • 6.2.2.2. Smallpox
      • 6.2.2.3. Botulism
      • 6.2.2.4. Chemical
      • 6.2.2.5. Radiation/Nuclear
      • 6.2.2.6. Others
    • 6.2.3. Asia Pacific Biodefense Market Share and BPS Analysis, by Product Type, Value, 2023 and 2030
    • 6.2.4. Asia Pacific Biodefense Market Attractiveness Analysis, by Product Type, Value, 2023 - 2030
  • 6.3. Asia Pacific Biodefense Market Outlook, By End Use, 2019 - 2030
    • 6.3.1. Key Highlights
    • 6.3.2. Asia Pacific Biodefense Market Outlook, by End Use, Value (US$ Million), 2019 - 2030
      • 6.3.2.1. Military
      • 6.3.2.2. Civil
      • 6.3.2.3. Research Institutes
    • 6.3.3. Asia Pacific Biodefense Market Share and BPS Analysis, by End Use, Value, 2023 and 2030
    • 6.3.4. Asia Pacific Biodefense Market Attractiveness Analysis, by End Use, Value, 2023 - 2030

7. Rest of the World Biodefense Market Outlook, 2019 - 2030

  • 7.1. Rest of the World Biodefense Market Outlook, By Country, 2019 - 2030
    • 7.1.1. Key Highlights
    • 7.1.2. Rest of the World Biodefense Market Outlook, by Country, Value (US$ Million), 2019 - 2030
      • 7.1.2.1. Latin America
      • 7.1.2.2. Middle East & Africa
    • 7.1.3. Rest of the World Biodefense Market Share and BPS Analysis, by Country, Value, 2023 and 2030
    • 7.1.4. Rest of the World Biodefense Market Attractiveness Analysis, by Country, Value, 2023 - 2030
  • 7.2. Rest of the World Biodefense Market Outlook, by Product Type, 2019 - 2030
    • 7.2.1. Key Highlights
    • 7.2.2. Rest of the World Biodefense Market Outlook, by Product Type, Value (US$ Million), 2019 - 2030
      • 7.2.2.1. Anthrax
      • 7.2.2.2. Smallpox
      • 7.2.2.3. Botulism
      • 7.2.2.4. Chemical
      • 7.2.2.5. Radiation/Nuclear
      • 7.2.2.6. Others
    • 7.2.3. Rest of the World Biodefense Market Share and BPS Analysis, by Product Type, Value, 2023 and 2030
    • 7.2.4. Rest of the World Biodefense Market Attractiveness Analysis, by Product Type, Value, 2023 - 2030
  • 7.3. Rest of the World Biodefense Market Outlook, By End Use, 2019 - 2030
    • 7.3.1. Key Highlights
    • 7.3.2. Rest of the World Biodefense Market Outlook, by End Use, Value (US$ Million), 2019 - 2030
      • 7.3.2.1. Military
      • 7.3.2.2. Civil
      • 7.3.2.3. Research Institutes
    • 7.3.3. Rest of the World Biodefense Market Share and BPS Analysis, by End Use, Value, 2023 and 2030
    • 7.3.4. Rest of the World Biodefense Market Attractiveness Analysis, by End Use, Value, 2023 - 2030

8. Competitive Landscape

  • 8.1. Heat Map Analysis
  • 8.2. Company Profiles
    • 8.2.1. Emergent Biosolutions, Inc.
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Financial Performance
      • 8.2.1.3. Product Portfolio
      • 8.2.1.4. Pipeline Analysis
    • 8.2.2. SIGA Technologies, Inc.
    • 8.2.3. Bavarian Nordik A/S
    • 8.2.4. GSK plc
    • 8.2.5. Sanofi Pasteur
    • 8.2.6. NightHawk Biosciences, Inc.
    • 8.2.7. Soligenix
    • 8.2.8. Arbutus Biopharma Corporation
    • 8.2.9. Altimmune
    • 8.2.10. Meridian Medical Technologies, LLC
    • 8.2.11. Others

9. Appendix

  • 9.1. Research Methodology
  • 9.2. Report Specific Research Approach